Kite Pharma, Inc. Spending and interest coverage
- R&D / revenue · 12 months: Value 787.09%; Formula and calculation Research and development expense / revenue. Period ending 2017-06-30..
- Stock-based compensation / revenue · 12 months: Value 274.45%; Formula and calculation Share-based compensation / revenue. Period ending 2017-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2017-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 787.09% | Research and development expense / revenue. Period ending 2017-06-30. $252.94M ÷ $32.14M × 100 ≈ 787.09% |
| Stock-based compensation / revenue · 12 months | 274.45% | Share-based compensation / revenue. Period ending 2017-06-30. $88.20M ÷ $32.14M × 100 ≈ 274.45% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 252.94M USD | Research and Development Expense |
| Revenue | 32.14M USD | |
| Stock-based compensation | 88.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -354.30M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2017-06-30 | $252.94M | $32.14M | $88.20M | $-354.30M | (m) | 787.09% | 274.45% | (m) | (m) |
| 2017-03-31 | $229.43M | $26.88M | $82.79M | $-319.13M | $17.00K | 853.55% | 308.01% | -18772.29× | Reported |
| 2016-12-31 | $197.93M | $22.17M | $73.58M | $-273.19M | $13.00K | 892.80% | 331.89% | -21014.38× | Reported |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $101.52M | $19.50M | $48.61M | $-134.30M | $22.00K | 520.52% | 249.22% | -6104.73× | Reported |
| 2015-12-31 | $76.37M | $17.26M | $40.42M | $-103.95M | $26.00K | 442.51% | 234.21% | -3998.08× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | $-36.66M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | $-6.43M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $1.81M | (m) | $30.00K | $-2.58M | $1.00K | (m) | (m) | -2581.00× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.